Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Angeion Corp. (ANGN) -- Ignore unavailable to you. Want to Upgrade?

To: ewolf who wrote (991)	3/4/1999 5:48:00 PM
From: jean	Read Replies (2) \| Respond to of 1046

ewolf and all ANGN... Here's an interesting post from Yahoo. Jean This is my first and probably last post (you have raised an interesting question). Yes, Angeion has had other offers. A complication is Angeion's involvement with ELA. To do a deal with someone else they must get untangled from the ELA joint venture. Angeion does have a very serious suitor in a European company other than ELA. This company was a bidder against Guidant in the Intermedics deal. There are major market forces at play. ELA, Sorin, Angeion and perhaps even Biotronic MUST join forces or do some consolidation to compete against megacompanies like Guidant (recent acquisitions include Incontrol and Intermedics), Medtronics and St. Jude. Small companies will no longer be viable in the pacer and ICD bus. Bundling, Dr. support (in and outside the OR), HMO massive buying plans, fast product to market cycles are just a few reasons. These European companies now have to join/consolidate to survive and they also must have an ICD. ELA has their own ICD, however, it is technologically way behind Angeion's 2020/2030. They must also be ready for the next products including devices that treat AF and/or all four chambers. Treatment of congestive heart failure with leads implanted in all four chambers will also be a big market. Angeion's impending FDA approval is a very big deal. Not only will it validate a meaningful product, but also will bring in $10M from ELA as part of their contracts. It will also be the last hurdle in bringing a deal together of some sort with the European Companies that I spoke of. Change is also afoot at ELA (new owners). The next four to eight weeks should be very interesting.